Pasar al contenido principal

MODULACION DE LA EPOXIDO HIDROLASA SOLUBLE (SEH) EN CEREBRO Y TEJIDOS PERIFERICOS: PAPEL DEL EJE INTESTINO-CEREBRO EN LA NEURODEGENERACION

PID2019-106285RB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease

  • Rodríguez Arévalo, Sergio
  • Bagán, Andrea
  • Griñán Ferré, Christian
  • Vasilopoulou, Foteini
  • Pallàs, Mercè
  • Brocos Mosquera, Iria
  • Callado, Luis F.
  • Loza García, María Isabel
  • Martínez Rodríguez, Antón Leandro
  • Brea Floriani, José Manuel
  • Pérez, Belén
  • Molins, Elies
  • De Jonghe, Steven
  • Daelemans, Dirk
  • Radan, Milica
  • Djikic, Teodora
  • Nikolic, Katarina
  • Hernández Hernández, Elena
  • García Fuster, M. Julia
  • García Sevilla, Jesús A.
  • Escolano, Carmen
Recent findings unveil the pharmacological modulation of imidazoline I2 receptors (I2-IR) as a novel strategy to face unmet medical neurodegenerative diseases. In this work, we report the chemical characterization, three-dimensional quantitative structure-activity relationship (3D-QSAR) and ADMET in silico of a family of benzofuranyl-2-imidazoles that exhibit affinity against human brain I2-IR and most of them have been predicted to be brain permeable. Acute treatment in mice with 2-(2-benzofuranyl)-2-imidazole, known as LSL60101 (garsevil), showed non-warning properties in the ADMET studies and an optimal pharmacokinetic profile. Moreover, LSL60101 induced hypothermia in mice while decreased pro-apoptotic FADD protein in the hippocampus. In vivo studies in the familial Alzheimer's disease 5xFAD murine model with the representative compound, revealed significant decreases in the protein expression levels of antioxidant enzymes superoxide dismutase and glutathione peroxidase in hippocampus. Overall, LSL60101 plays a neuroprotective role by reducing apoptosis and modulating oxidative stress
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antibody protection against long-term memory loss induced by monomeric c-reactive protein in a mouse model of dementia

  • García-Lara, Elisa
  • Aguirre Infantes, Samuel
  • Clotet Perarnau, Núria
  • Sawkulycz, Xenia
  • Bartra Cabré, Clara
  • Almenara-Fuentes, Lidia
  • Suñol, Cristina
  • Corpas, Rubén
  • Olah, Peter
  • Tripon, Florin
  • Crauciuc, Andrei
  • Slevin, Mark
  • Sanfeliu, Coral
Monomeric C-reactive protein (mCRP), the activated isoform of CRP, induces tissue damage in a range of inflammatory pathologies. Its detection in infarcted human brain tissue and its experimentally proven ability to promote dementia with Alzheimer’s disease (AD) traits at 4 weeks after intrahippocampal injection in mice have suggested that it may contribute to the development of AD after cerebrovascular injury. Here, we showed that a single hippocampal administration of mCRP in mice induced memory loss, lasting at least 6 months, along with neurodegenerative changes detected by increased levels of hyperphosphorylated tau protein and a decrease of the neuroplasticity marker Egr1. Furthermore, co-treatment with the monoclonal antibody 8C10 specific for mCRP showed that long-term memory loss and tau pathology were entirely avoided by early blockade of mCRP. Notably, 8C10 mitigated Egr1 decrease in the mouse hippocampus. 8C10 also protected against mCRP-induced inflammatory pathways in a microglial cell line, as shown by the prevention of increased generation of nitric oxide. Additional in vivo and in vitro neuroprotective testing with the anti-inflammatory agent TPPU, an inhibitor of the soluble epoxide hydrolase enzyme, confirmed the predominant involvement of neuroinflammatory processes in the dementia induced by mCRP. Therefore, locally deposited mCRP in the infarcted brain may be a novel biomarker for AD prognosis, and its antibody blockade opens up therapeutic opportunities for reducing post-stroke AD risk., This research was funded by the European Competitiveness Operational Programme 2014– 2020, C-Reactive protein therapy for stroke-associated dementia, ID P_37_674, MySMIS code: 103432, contract 51/05.09.2016; Spanish MINECO and European Regional Development Fund, grant number SAF2016-77703; Spanish MCINN, grant number PID2019-106285RB; Catalan Autonomous Government AGAUR, grant number 2017-SGR-106; the CERCA Programme/Generalitat de Catalunya. R.C was supported by a post-doctoral research contract of the Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microglial hyperreactivity evolved to immunosuppression in the hippocampus of a mouse model of accelerated aging and Alzheimer’s Disease traits

  • Molina-Martínez, Patricia
  • Corpas, Rubén
  • García-Lara, Elisa
  • Cosín-Tomás, Marta
  • Cristòfol, Rosa
  • Kaliman, Perla
  • Solà, Carme
  • Molinuevo, José Luis
  • Sánchez-Valle, Raquel
  • Antonell, Anna
  • Lladó, Albert
  • Sanfeliu, Coral
Neuroinflammation is a risk factor for Alzheimer’s disease (AD). We sought to study the glial derangement in AD using diverse experimental models and human brain tissue. Besides classical pro-inflammatory cytokines, we analyzed chitinase 3 like 1 (CHI3L1 or YKL40) and triggering receptor expressed on myeloid cells 2 (TREM2) that are increasingly being associated with astrogliosis and microgliosis in AD, respectively. The SAMP8 mouse model of accelerated aging and AD traits showed elevated pro-inflammatory cytokines and activated microglia phenotype. Furthermore, 6-month-old SAMP8 showed an exacerbated inflammatory response to peripheral lipopolysaccharide in the hippocampus and null responsiveness at the advanced age (for this strain) of 12 months., This research was funded by Spanish MINECO and European Regional Development Fund, grant number SAF2016- 77703; Spanish MCINN, grant number PID2019-106285RB; Catalan Autonomous Government AGAUR, grant number 2017-SGR-106; Competitiveness Operational Programme 2014-2020, C-Reactive protein therapy for stroke-associated dementia, ID P_37_674, MySMIS code: 103432, contract 51/05.09.2016; and the CERCA Programme/Generalitat de Catalunya. RCo was supported by a post-doctoral research contract of the Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. AL (PERIS SLT008/18/00061) received funding from Departament de Salut de la Generalitat de Catalunya. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Resveratrol confers neuroprotection against high-fat diet in a mouse model of Alzheimer's disease via modulation of proteolytic mechanisms

  • Sarroca, Sara
  • Gatius, Alaó
  • Rodríguez-Farré, Eduard
  • Vilchez, David
  • Pallàs, Mercè
  • Griñán-Ferré, Christian
  • Sanfeliu, Coral
  • Corpas, Rubén
Cumulative evidence indicates that excessive consumption of calories from saturated fat contributes to the development of Alzheimer's disease (AD). Here, we assess the triggering and progression of AD pathology induced by a high-fat diet (HFD), and the effects of resveratrol, a polyphenol found in common dietary sources with pleiotropic neuroprotective activities. Over 16 weeks, male wild type (WT) and AD transgenic 5XFAD mice were fed a control diet, HFD (60% kcal from fat), or HFD supplemented with 0.1% resveratrol. Resveratrol protected against HFD-induced memory loss in WT mice and prevented memory loss in 5XFAD mice. Resveratrol also reduced the amyloid burden aggravated by HFD in 5XFAD, and protected against HFD-induced tau pathology in both WT and 5XFAD strains. At the mechanistic level, resveratrol inhibited the HFD-increased amyloidogenic processing of the amyloid precursor protein in both strains; it also restored abnormal high levels in the proteolytic activity of the ubiquitin-proteasome system induced by HFD, suggesting the presence of a compensatory mechanism to counteract the accumulation of aberrant proteins. Thus, our data suggest that resveratrol can correct the harmful effects of HFD in the brain and may be a potential therapeutic agent against obesity-related disorders and AD pathology., This research was funded by Spanish MINECO and European Regional Development Fund (grant number SAF2016-77703-C2); Spanish MCINN (grant number PID2019-106285RB); Catalan Autonomous Government AGAUR (grant number 2017-SGR-106); and the CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer¿s disease pathology: from antioxidant to epigenetic therapy

  • Griñán-Ferré, Christian
  • Bellver-Sanchis, Aina
  • Izquierdo, Vanesa
  • Corpas, Rubén
  • Roig-Soriano, Joan
  • Chillón, Miguel
  • Andrés-Lacueva, Cristina
  • Somogyvári, Milán
  • Sőti, Csaba
  • Sanfeliu, Coral
  • Pallàs, Mercè
increase exponentially. Lifestyle factors such as nutrition, exercise, and education, among others, influence ageing progression, throughout life. Notably, the Central Nervous System (CNS) can benefit from nutritional strategies and dietary interventions that prevent signs of senescence, such as cognitive decline or neurodegenerative diseases such as Alzheimer¿s disease and Parkinson¿s Disease. The dietary polyphenol Resveratrol (RV) possesses antioxidant and cytoprotective effects, producing neuroprotection in several organisms. The oxidative stress (OS) occurs because of Reactive oxygen species (ROS) accumulation that has been proposed to explain the cause of the ageing. One of the most harmful effects of ROS in the cell is DNA damage. Nevertheless, there is also evidence demonstrating that OS can produce other molecular changes such as mitochondrial dysfunction, inflammation, apoptosis, and epigenetic modifications, among others. Interestingly, the dietary polyphenol RV is a potent antioxidant and possesses pleiotropic actions, exerting its activity through various molecular pathways. In addition, recent evidence has shown that RV mediates epigenetic changes involved in ageing and the function of the CNS that persists across generations. Furthermore, it has been demonstrated that RV interacts with gut microbiota, showing modifications in bacterial composition associated with beneficial effects. In this review, we give a comprehensive overview of the main mechanisms of action of RV in different experimental models, including clinical trials and discuss how the interconnection of these molecular events could explain the neuroprotective effects induced by RV., This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) (PID2019-106285RB and PCIN-2015-229, and Generalitat de Catalunya (2017 SGR 106) to M.P. The work was funded by grants from the Hungarian Science Foundation (OTKA K 116525), and from the Semmelweis University (STIA-KFI-2020/132257/AOMBT/2020) to C.S.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Implicación de la proteína C reactiva monomérica en el desarrollo de demencia de tipo Alzheimer: modelo experimental y posibles terapias

  • García-Lara, Elisa
Tesis doctoral presentada para lograr el título de Doctor en Biomedicina por la Universidad de Barcelona, Facultad de Medicina y Ciencias de la Salud.--2021-02-19.--Excelente, La neuroinflamación sostenida es un factor de riesgo de enfermedades relacionadas con la edad, incluidas las lesiones cerebrovasculares y la enfermedad de Alzheimer (EA). De hecho, los procesos inflamatorios se consideran cada vez más los culpables de la fragilidad y la enfermedad de la población envejecida. Como resultado, se ha intensificado la búsqueda de biomarcadores inflamatorios fiables y objetivos de intervención para combatir la demencia y otras enfermedades discapacitantes. Cada año se registran cerca de 8 millones de nuevos casos de demencia, y se estima que, para el 2050, la demencia afecte a 150 millones de personas. La enfermedad de Alzheimer (EA) es la más prevalente de las demencias, suponiendo entre un 60 y un 70% de todos los casos de demencia. Esta enfermedad se caracteriza por la pérdida cognitiva y de memoria, junto a la presentación de síntomas conductuales y psicológicos asociados a la demencia (BPSD) que disminuyen de manera drástica la calidad de vida del paciente y sus cuidadores. La neuropatología de la EA se caracteriza por el depósito proteico del péptido amiloide y tau hiperfosforilada que, eventualmente, desembocan en la agregación de placas seniles y ovillos neurofibrilares. Esta patología además, suele ir acompañada de neuroinflamación, aumento del extrés oxidativo y disfunción mitocondrial, alteración neurovascular, pérdida sináptica y neurodegeneración. Actualmente no existe cura para el Alzheimer, por ello, nuevas terapias que aborden su prevención o presenten nuevas vías de investigación son imprescindibles. En esta tesis se ha pretendido evaluar la contribución de la proteína monomérica C-reactiva al desarrollo de demencia de tipo EA. La proteína C-Reactiva (CRP) es una pentraxina, secretada por el hígado en respuesta a la inflamación y ampliamente conocida por ser un marcador de procesos inflamatorios. Así cuando el pentaméro que es la CRP se une a las membranas de los tejidos dañados, esta se disocia dando lugar a sus subunidades monoméricas, altamente pro-inflamatorias y poco solubles, que quedan depositadas de manera crónica en la matriz extracelular del tejido afectado. La proteína monomérica C-reactiva es, por lo tanto, una de las subunidades monoméricas de la CRP. Así, la mCRP depositada en la matriz extracelular del tejido dañado favorece un ambiente proinflamatorio crónico que, sumado a su alta capacidad angiogénica favorece el agravamiento de la enfermedad. Estudios recientes han confirmado la presencia de mCRP en el tejido cerebral de enfermos de EA, así como la capacidad de las placas amiloides para disociar CRP generando mCRP. Asimismo, se ha demostrado cómo mCRP favorece la fosforilización de tau in vitro y cómo la tau fosforilada colocaliza a nivel intraneuronal con mCRP en cerebros de pacientes de EA., Por otra parte, estudios previos de nuestro grupo de investigación desmotraron que la mCRP inyectada en el hipocampo de ratones inducía pérdida de memoria después de 4 semanas, así como otros rasgos de la EA, como patología amiloide y de tau en neuronas del hipocampo y áreas corticales. Estos estudios también han confirmado a mCRP como un posible vínculo entre el ictus y el posterior desarrollo de demencia que aparece en un tercio de los casos de accidente cerebrovascular. Así, la hipótesis en que se basa esta tesis es que la mCRP, la forma activada de la CRP, contribuye al desarrollo y progresión de la enfermedad de EA. Con el fin de probar esta hipotésis, desarrollamos un modelo de ratón de demencia inducido mediante la infusión bilateral de mCRP en el hipocampo de los ratones. Los animales fueron evaluados tras 1, 3 y 6 meses de tratamiento con mCRP con el fin de caracterizar la pérdida cognitiva y de BPSD de este modelo, así como la neuropatología adyacente. Posteriormente se realizó otro estudio en el que se utilizó el modelo de demencia inducido por mCRP para evaluar si el tratamiento con un anticuerpo monoclonal anti-mCRP era capaz de bloquear los efectos patológicos inducidos por esta a 1, 3 y 6 meses de tratamiento. Asimismo, tambien evaluamos los posibles efectos protectores del antiinflamatorio TPPU en nuestro modelo de demencia por mCRP a 1 mes de tratamiento. Nuestros estudios in vivo fueron complementados por estudios in vitro en los que evaluamos la respuesta de la línea de microglía BV2 ante mCRP, así como la posible inhibición de los efectos proinflamatorios de mCRP mediante el anticuerpo monoclonal anti-mCRP y el antiinflmatorio TPPU. Nuestros resultados revelaron que: -La inyección estereotáxica bilateral de mCRP en el hipocampo de ratones adultos indujo pérdida cognitiva a 1, 3 y 6 meses de tratamiento, y aparición de BPSD a los 6 meses de tratamiento. -mCRP permaneció en el hipocampo de los ratones desde 1 mes hasta 6 meses después del tratamiento, diseminándose de manera parcial hasta el córtex y el hipocampo. -mCRP indujo, en los lugares donde se deposita; neuroinflamación y aparición del péptido amiloide de manera local y fosforilación de tau y pérdida de la plasticidad de manera generalizada en el hipocampo. -Los efectos deletereos inducidos por mCRP fueron bloqueados por el anticuerpo monoclonal anti-mCRP tanto a nivel cognitivo y conductual como a nivel molecular. -El antiinflamatorio TPPU inhibió la pérdida cognitiva inducida por mCRP en nuestro modelo de ratón tras un mes de tratamiento. -mCRP indujo inflamación microglial que fue bloqueada tanto por el anticuerpo monoclonal anti-mCRP como por el antiinflamatorio TPPU. Así, en esta tesis se demuestra la implicación de la proteína mCRP en el desarrollo de demencia de tipo EA y se presenta un nuevo modelo de demencia por inyección de mCRP, así como posibles tratamientos que bloqueen la actividad deleterea de mCRP disminuyendo sus efectos adversos en la EA. Finalmente, el bloqueo específico de mCRP es una terapia prometedora para reducir la neurodegeneración después de una lesión cerebrovascular y el desarrollo de EA, la forma más común de demencia en la población anciana. Además, la mCRP puede ser un biomarcador útil del pronóstico de procesos neurodegenerativos asociados a la neuroinflamación, puediendo detectarse mediante técnicas no invasivas. Los avances en la detección de mCRP y los enfoques terapéuticos contra esta presentan nuevas perspectivas en la lucha contra las condiciones patológicas afectadas por la interacción dañina entre mCRP y células y tejidos.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glial cell reactivity and oxidative stress prevention in Alzheimer’s disease mice model by an optimized NMDA receptor antagonist

  • Companys-Alemany, Júlia
  • Turcu, Andreea L.
  • Vázquez, Santiago
  • Pallàs, Mercè
  • Griñán-Ferré, Christian
In Alzheimer's disease pathology, several neuronal processes are dysregulated by excitotoxicity including neuroinflammation and oxidative stress (OS). New therapeutic agents capable of modulating such processes are needed to foster neuroprotection. Here, the effect of an optimised NMDA receptor antagonist, UB-ALT-EV and memantine, as a gold standard, have been evaluated in 5XFAD mice. Following treatment with UB-ALT-EV, nor memantine, changes in the calcineurin (CaN)/NFAT pathway were detected. UB-ALT-EV increased neurotropic factors (Bdnf, Vgf and Ngf) gene expression. Treatments reduced astrocytic and microglial reactivity as revealed by glial fibrillary acidic protein (GFAP) and ionized calcium-binding adapter molecule 1 (Iba-1) quantification. Interestingly, only UB-ALT-EV was able to reduce gene expression of Trem2, a marker of microglial activation and NF-κB. Pro-inflammatory cytokines Il-1β, Ifn-γ, Ccl2 and Ccl3 were down-regulated in UB-ALT-EV-treated mice but not in memantine-treated mice. Interestingly, the anti-inflammatory markers of the M2-migroglial phenotype, chitinase-like 3 (Ym1) and Arginase-1(Arg1), were up-regulated after treatment with UB-ALT-EV. Since iNOS gene expression decreased after UB-ALT-EV treatment, a qPCR array containing 84 OS-related genes was performed. We found changes in Il-19, Il-22, Gpx6, Ncf1, Aox1 and Vim gene expression after UB-ALT-EV. Hence, our results reveal a robust effect on neuroinflammation and OS processes after UB-ALT-EV treatment, surpassing the memantine effect in 5XFAD., Tis study was supported by PID2019-106285RB, PDC2021-121096 MDM-2017-0729 funded by MCIN/AEI/10.13039/501100011033; 2017SGR106 (AGAUR, Catalonia). J.C.-A. acknowledge Ministry of Economy and Competitiveness (MINECO) for her FPI (MDM-2017-0729) fellowship. A.L.T. acknowledges a PhD fellowship (FPU Grant) from the Spanish Ministerio de Educación, Cultura y Deporte.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Pharmacological inhibition of soluble epoxide hydrolase during brain development induces long-term benefices in 5XFAD mice

  • Villoslada, Ainhoa
  • Bartra Cabré, Clara
  • Irisarri Martínez, Marta
  • Corpas, Rubén
  • Suñol, Cristina
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Sanfeliu, Coral
Trabajo presentado en el XII Simposi de Neurobiologia, Societat Catalana de Biologia, celebrado en Barcelona (España), los días 7 y 8 de junio de 2022, Modulation of the risk of Alzheimer¿s disease (AD) may begin early in life. During embryo development and maturation, the brain receives maternal physiological influences and establishes new epigenetic patterns that build its level of resilience to late diseases. We treated wild-type pregnant mice with the soluble epoxide hydrolase (sEH) inhibitor TPPU until their pups were weaned. The male progenitors were AD transgenic mice from the strain 5XFAD. At two months of age, male and female mice were blindly analyzed for learning and memory performance and their brain tissue was preserved for further analysis. Once genotyped, we found that 5XFAD mice worn from vehicle-treated mothers showed a poor response in cognitive tests of object recognition and spatial location. Notably, those 5XFAD mice from TPPU-treated mothers showed similar performance to their wild-type siblings. At the molecular level, tau pathology shown by increased hippocampal p-tau levels in 5XFAD mice was totally prevented in those whose mothers were treated with TPPU. Furthermore, TPPU treatment also modified the expression of epigenetic markers. Overall, we confirmed the potential of the enzyme sEH as a new target to fight AD and demonstrated that its inhibition in the developing brain produces long-term preventive effects against neurodegeneration., MCIN/AEI (PID2019-106285RB); AGAUR (2017-SGR-106); CSIC (2019AEP038).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Synthesis, in vitro profiling and in vivo evaluation of benzohomoadamantane-based ureas for visceral pain: a new indication for soluble epoxide hydrolase inhibitors

  • Codony, Sandra
  • Entrena, José M.
  • Calvó-Tusell, Carla
  • Osuna, Sílvia
  • Jora, Beatrice
  • González-Cano, Rafael
  • Corpas, Rubén
  • Morisseau, Christophe
  • Pérez, Belén
  • Barniol-Xicota, Marta
  • Griñán-Ferré, Christian
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Martínez, Antón L.
  • Loza, María Isabel
  • Pallàs, Mercè
  • Verhelst, Steven H. L.
  • Sanfeliu, Coral
  • Feixas, Ferran
  • Hammock, Bruce D.
  • Brea, José Manuel
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based sEH inhibitors (sEHI) in order to improve the drug metabolism and pharmacokinetics properties of a previous hit. After an extensive in vitro screening cascade, molecular modeling, and in vivo pharmacokinetics studies, two candidates were evaluated in vivo in a murine model of capsaicin-induced allodynia. The two compounds showed an anti-allodynic effect in a dose-dependent manner. Moreover, the most potent compound presented robust analgesic efficacy in the cyclophosphamide-induced murine model of cystitis, a well-established model of visceral pain. Overall, these results suggest painful bladder syndrome as a new possible indication for sEHI, opening a new range of applications for them in the visceral pain field., This work was funded by the Spanish Ministerio de Economía, Industria y Competitividad (grants SAF2017-82771-R to S.V., RTI2018-093955-B-C21 to M.I.R.-F., PGC2018-102192-B-I00 to S.O. and RTI2018-101032-J-I00 to F.F.), the Spanish MCIN/AEI/10.13039/501100011033 and “ERDF A way of making Europe” (Grant PID2020-118127RB-I00 to S.V. and Grant PID2019-106285RB to M.P. and C.S.) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), the Generalitat de Catalunya (2017 SGR 106 and 2017 SGR 1707), the European Research Council (ERC-2015-StG-679001-NetMoDEzyme to S.O.), and the European Community (MSCA-IF-2014-EF661160-MetAccembly to F.F.). S.C. acknowledges a PhD fellowship from the Universitat de Barcelona (APIF grant) and the Spanish Society of Medicinal Chemistry (SEQT) and Lilly for an “Award for Novel Researchers in the Discovery and Development of New Drugs”. M.B.X. acknowledges FWO for a post-doctoral fellowship (no. 12Y0720N). S.H.L.V. acknowledges the Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, the Regierende Bürgermeister von Berlin, and the Bundesministerium für Bildung und Forschung. F.F. acknowledges Spanish MICINN for a Ramón y Cajal fellowship (RYC2020-029552-I). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroprotective Epigenetic Changes Induced by Maternal Treatment with an Inhibitor of Soluble Epoxide Hydrolase Prevents Early Alzheimer′s Disease Neurodegeneration

  • Bartra Cabré, Clara
  • Irisarri Martínez, Marta
  • Villoslada, Ainhoa
  • Corpas, Rubén
  • Aguirre Infantes, Samuel
  • García-Lara, Elisa
  • Suñol, Cristina
  • Pallàs, Mercè
  • Griñán-Ferré, Christian
  • Sanfeliu, Coral
Modulation of Alzheimer′s disease (AD) risk begins early in life. During embryo development and postnatal maturation, the brain receives maternal physiological influences and establishes epigenetic patterns that build its level of resilience to late-life diseases. The soluble epoxide hydrolase inhibitor N-[1-(1-oxopropyl)-4-piperidinyl]-N′-[4-(trifluoromethoxy)phenyl] urea (TPPU), reported as ant-inflammatory and neuroprotective against AD pathology in the adult 5XFAD mouse model of AD, was administered to wild-type (WT) female mice mated to heterozygous 5XFAD males during gestation and lactation. Two-month-old 5XFAD male and female offspring of vehicle-treated dams showed memory loss as expected. Remarkably, maternal treatment with TPPU fully prevented memory loss in 5XFAD. TPPU-induced brain epigenetic changes in both WT and 5XFAD mice, modulating global DNA methylation (5-mC) and hydroxymethylation (5-hmC) and reducing the gene expression of some histone deacetylase enzymes (Hdac1 and Hdac2), might be on the basis of the long-term neuroprotection against cognitive impairment and neurodegeneration. In the neuropathological analysis, both WT and 5XFAD offspring of TPPU-treated dams showed lower levels of AD biomarkers of tau hyperphosphorylation and microglia activation (Trem2) than the offspring of vehicle-treated dams. Regarding sex differences, males and females were similarly protected by maternal TPPU, but females showed higher levels of AD risk markers of gliosis and neurodegeneration. Taken together, our results reveal that maternal treatment with TPPU impacts in preventing or delaying memory loss and AD pathology by inducing long-term modifications in the epigenetic machinery and its marks., This research was funded by the Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB and PDC2021-121096) and by the European Union “NextGenerationEU”/PRTR; CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2017SGR106 from AGAUR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease

  • Codony, Sandra
  • Pont, Caterina
  • Griñán-Ferré, Christian
  • Di Pede-Mattatelli, Ania
  • Calvó-Tusell, Carla
  • Feixas, Ferran
  • Osuna, Sílvia
  • Jarné-Ferrer, Júlia
  • Naldi, Marina
  • Bartolini, Manuela
  • Loza, María Isabel
  • Brea, José Manuel
  • Pérez, Belén
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Juárez-Jiménez, Jordi
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Pallàs, Mercè
  • Vázquez, Santiago
  • Muñoz-Torrero, Diego
With innumerable clinical failures of target-specific drug candidates for multifactorial diseases, such as Alzheimer's disease (AD), which remains inefficiently treated, the advent of multitarget drug discovery has brought a new breath of hope. Here, we disclose a class of 6-chlorotacrine (huprine)-TPPU hybrids as dual inhibitors of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE), a multitarget profile to provide cumulative effects against neuroinflammation and memory impairment. Computational studies confirmed the gorge-wide occupancy of both enzymes, from the main site to a secondary site, including a so far non-described AChE cryptic pocket. The lead compound displayed in vitro dual nanomolar potencies, adequate brain permeability, aqueous solubility, human microsomal stability, lack of neurotoxicity, and it rescued memory, synaptic plasticity, and neuroinflammation in an AD mouse model, after low dose chronic oral administration., This work was supported by grants PID2020-118127RB-I00, SAF2017-82771-R, PID2020-115683GA-I00, PGC2018- 102192-B-I00, PID2019-106285RB, and RTI2018-101032-JI00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, ED431C 2018/21 and ED431G 2019/02 from Xunta de Galicia, and 2017SGR106, 2017SGR1707, and 2019LLAV00017 from AGAUR. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Fellowships from Ministerio de Educación, Cultura y Deporte to C.P. (FPU15/01131), from the University of Barcelona to S.C., and a starting grant from the European Research Council (ERC-2015-StG-679001- NetMoDEzyme) to S.O. are gratefully acknowledged. We thank Ms. Cecilia Mariani for technical assistance in the assays with mAChE., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

High levels of anti-inflammatory epoxyeicosatrienoic acids may improve neurodevelopment in children prenatally exposed to mercury

  • Sanfeliu, Coral
  • Bartra Cabré, Clara
  • Llop, Sabrina
  • Kuligowski, Julia
  • Albiach-Delgado, Abel
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
  • Ballester, Ferrán
  • Soler-Blasco, Raquel
  • Jora, Beatrice
  • Jarné-Ferrer, Júlia
  • Griñán-Ferré, Christian
  • Vázquez, Santiago
  • Pallàs, Mercè
Trabajo presentado en Neuroscience 2023, celebrado en Washington D. C. (Estados Unidos), del 11 al 15 de noviembre de 2023, A balanced concentration of polyunsaturated fatty acids (PUFA) in the prenatal stage is essential for children¿s neurodevelopment. Also, animal studies showed that high levels of anti-inflammatory PUFA metabolites in the embryonic brain protect against genetic or environmental insults that would otherwise cause cognitive impairment. Here we used liquid chromatography - mass spectrometry to analyze oxylipins, the oxygenated metabolites of PUFA, in the placenta tissue (N=12) and cord blood plasma (N=39) of children from the INMA cohort (Valencia, Spain). Both tissues were characterized for total Hg levels as a reference for developmental neurotoxic MeHg exposure during pregnancy and distributed in low and high Hg groups. Deleterious effects of high Hg were confirmed in the placenta as decreased proteasome activity and inhibitory epigenetic changes. Children¿s neurodevelopment was assessed using the Bayley (14 months) and McCarthy (5 years) scales. Spearman correlation coefficients were calculated between scores and oxylipin levels. We also analyzed cortical brain tissue from wild type and transgenic Alzheimer's disease (5XFAD) mice dosed for 2 months with vehicle or a soluble epoxide hydrolase enzyme (sEH) inhibitor, UB-BJ-02 (5 mg/Kg, N=5/group). Inhibition of sEH increases levels of the potent anti-inflammatory epoxyeicosatrienoic acids (EETs) by inhibiting their hydrolysis to dihydro-EETs (DiHETs). We found that DiHETs were increased in the placenta of high Hg group. Furthermore, the mental and psychomotor development of 14-month-old children correlates positively with DiHETs levels in both placenta and cord blood tissues. Interestingly, cord blood DiEHTs positively correlate with working memory at 5 years. Thus we suggest that higher levels of DiHETs indicate higher synthesis of their anti-inflammatory EETs precursors. Accordingly, placenta levels of EETs correlate with mental development at 14 months of age. Other oxylipin changes also suggested an involvement of inflammatory mechanisms in the neurodevelopment of children exposed to MeHg. In general, higher levels of markers of resolved inflammation or final stable metabolites in the placenta and cord blood tissues correlate with better neuropsychological development in children exposed to environmental MeHg. Finally, mouse treatment with the drug UB-BJ-02 showed increased EETs and decreased pro-inflammatory markers in brain tissue. Both human and experimental results showed that EETs are prominent anti-inflammatory metabolites and support sEH inhibition as an anti-inflammatory treatment to increase brain resilience to environmental risk of neurodevelopmental damage., Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB and PDC2021-121096); European Union “NextGenerationEU”/PRTR; CERCA program/Generalitat de Catalunya; 2021-SGR-357 from AGAUR; H2020 874583; FIS/FEDER 19/1338; 16/1288; AICO/2020/285; CIAICO/2021/132; MS20/0006; MS21/0133
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Resveratrol is protective in Alzheimer's disease models of inflammation

  • Sanfeliu, Coral
  • Bartra Cabré, Clara
  • Yuan, Yi
  • Vuraić, Kristijan
  • García-Baucells, Pau
  • Valdés-Quiroz, Haydeé
  • Suñol, Cristina
Trabajo presentado en el 16th World Congress on Polyphenols Applications, celebrado en Malta los días 28 y 29 de septiembre de 2023, Introduction: Resveratrol is a polyphenol with known health benefits. We had demonstrated its antioxidant and antiaging effects in lymphocytes from Alzheimer¿s disease (AD) patients (1) and its cognitive enhancement and anti-amyloid and anti-tau pathology mechanisms in mouse models of AD (2). Here we analyzed in vitro the anti-inflammatory mechanisms of resveratrol against dementia-inducing monomeric Creactive protein (mCRP) (3). We also tested the anti-senescence effects of resveratrol in saturated fat models of neurodegeneration., Spanish MCIN/AEI/10.13039/501100011033 (PID2019-106285RB and PDC2021-121096); CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble epoxide hydrolase inhibitors counteract microglia pro-inflammatory response induced by monomeric C-reactive protein

  • Bartra Cabré, Clara
  • Vuraić, Kristijan
  • Yuan, Yi
  • Valdés-Quiroz, Haydeé
  • Codony, Sandra
  • Sawkulycz, Xenia
  • Slevin, Mark
  • Vázquez, Santiago
  • Suñol, Cristina
  • Sanfeliu, Coral
Neuroinflammation is a crucial neuropathological trait in Alzheimer’s disease (AD), although its role in the development of AD is not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of circulating CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology when injected into mouse hippocampus [1]. Furthermore, treatment of pregnant mice with TPPU, an inhibitor of the soluble epoxide hydrolase enzyme (sEH) with anti-inflammatory properties, successfully prevented memory loss and AD pathology in the offspring by inducing long-term modifications in the epigenetic machinery [2]., Spanish Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB-I00 and PDC2021-121096); CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Soluble epoxide hydrolase inhibitors counteract microglia pro-inflammatory response induced by monomeric C-reactive protein

  • Bartra Cabré, Clara
  • Vuraić, Kristijan
  • Yuan, Yi
  • Valdés-Quiroz, Haydeé
  • Codony, Sandra
  • Sawkulycz, Xenia
  • Slevin, Mark
  • Vázquez, Santiago
  • Suñol, Cristina
  • Sanfeliu, Coral
Trabajo presentado en el 36th ECNP Congress, celebrado en Barcelona (España), del 7 al 10 de octubre de 2023, Neuroinflammation is a crucial neuropathological trait in Alzheimer’s disease (AD), although its role in the development of AD is not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of circulating CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology when injected into mouse hippocampus [1]. Furthermore, treatment of pregnant mice with TPPU, an inhibitor of the soluble epoxide hydrolase enzyme (sEH) with anti-inflammatory properties, successfully prevented memory loss and AD pathology in the offspring by inducing long-term modifications in the epigenetic machinery [2]., Funding: Spanish Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB-I00 and PDC2021-121096); CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New insights in animal models of neurotoxicity-induced neurodegeneration

  • Sanfeliu, Coral
  • Bartra Cabré, Clara
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
The high prevalence of neurodegenerative diseases is an unintended consequence of the high longevity of the population, together with the lack of effective preventive and therapeutic options. There is great pressure on preclinical research, and both old and new models of neurodegenerative diseases are required to increase the pipeline of new drugs for clinical testing. We review here the main models of neurotoxicity-based animal models leading to central neurodegeneration. Our main focus was on studying how changes in neurotransmission and neuroinflammation, mainly in rodent models, contribute to harmful processes linked to neurodegeneration. The majority of the models currently in use mimic Parkinson's disease (PD) and Alzheimer's disease (AD), which are the most common neurodegenerative conditions in older adults. AD is the most common age-related dementia, whereas PD is the most common movement disorder with also cases of dementia. Several natural toxins and xenobiotic agents induce dopaminergic neurodegeneration and can reproduce neuropathological traits of PD. The literature analysis of MPTP, 6-OH-dopamine, and rotenone models suggested the latter as a useful model when specific doses of rotenone were administrated systemically to C57BL/6 mice. Cholinergic neurodegeneration is mainly modelled with the toxin scopolamine, which is a useful rodent model for the screening of protective drugs against cognitive decline and AD. Several agents have been used to model neuroinflammation-based neurodegeneration and dementia in AD, including lipopolysaccharide (LPS), streptozotocin, and monomeric C-reactive protein. The bacterial agent LPS makes a useful rodent model for testing anti-inflammatory therapies to halt the development and severity of AD. However, neurotoxin models might be more useful than genetic models for drug discovery in PD but that is not the case in AD where they cannot beat the new developments in transgenic mouse models. Overall, we should work using all available models, either in vivo, in vitro, or in silico, considering the seriousness of the moment and urgency of developing effective drugs., This research was funded by the Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB and PDC2021-121096) and by the European Union “NextGenerationEU”/PRTR; CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics

  • Griñán-Ferré, Christian
  • Jarné-Ferrer, Júlia
  • Bellver-Sanchís, Aina
  • Codony, Sandra
  • Puigoriol-Illamola, Dolors
  • Sanfeliu, Coral
  • Oh, Yumin
  • Lee, Seulki
  • Vázquez, Santiago
  • Pallàs, Mercè
Neuroinflammation is widely recognized as a significant hallmark of Alzheimer's disease (AD). To combat neuroinflammation, the inhibition of the soluble epoxide hydrolase (sEH) enzyme has been demonstrated crucial. Importantly, sEH inhibition could be related to other neuroprotective pathways described in AD., This work was supported by Spanish Ministerio de Ciencia e Innovación (PID2019-106285/AEI/10.13039/501100011033; PDC2021-121096/AEI/10.13039/501100011033; María de Maeztu Unit of Excellence to Institute of Neurosciences, University of Barcelona, MDM-2017-0729) and 2021SGR357 (AGAUR, Catalonia). ABS acknowledges a FI SDUR (2021 FI-B0812) fellowship to AGAUR Catalonia., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microglial pro-inflammatory mechanisms induced by monomeric C-reactive protein are counteracted by soluble epoxide hydrolase inhibitors

  • Bartra, Clara
  • Vuraić, Kristijan
  • Yuan, Yi
  • Codony, Sandra
  • Valdés-Quiroz, Haydeé
  • Casal, Carme
  • Slevin, Mark
  • Máquez-Kisinousky, Leonardo
  • Planas, Anna M.
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Vázquez, Santiago
  • Suñol, Cristina
  • Sanfeliu, Coral
Monomeric C-reactive protein (mCRP) is a pro-inflammatory molecule generated by the dissociation of native CRP. Clinical and experimental studies suggest that mCRP deposition in the brain induces Alzheimer's disease (AD) pathology and cognitive loss. Pathological neuroinflammation is increasingly suggested as relevant in AD. Innovative therapies against neuroinflammation are desperately needed, and inhibitors of the enzyme soluble epoxide hydrolase (sEH) are a promising new generation of anti-inflammatory drugs. Mouse primary microglia and BV2 cell line cultures were exposed to mCRP to analyze its pro-inflammatory mechanisms. sEH inhibitors, both newly synthesized UB-SCG-55 and UB-SCG-65, and the reference agent TPPU, were tested for their anti-inflammatory action against mCRP. Phenotypic changes were analyzed through cell imaging techniques, as well as molecular analysis of inflammatory mediators and gene activation pathways. Results show that mCRP triggers a pro-inflammatory response through three main inflammatory pathways: iNOS, NLRP3, and COX-2, followed by increased cytokine generation. Polarization of microglia toward a M1-like phenotype was confirmed by morphological analysis. Also, mCRP can bind to and cross the cell membrane, providing further insight into its mechanisms of action. sEH inhibitors were effective against mCRP induction of a reactive microglial phenotype. The first-line compound UB-SCG-55 emerged as the most potent anti-inflammatory against mCRP injury. Therefore, the direct activation of microglia by mCRP provides evidence of its role in triggering and exacerbating neurodegenerative diseases with a neuroinflammatory component, such as AD. Furthermore, the protection given by inhibitors of sEH confirms its potential as innovative drugs against deleterious effects of neuroinflammation., This research was funded by Spanish MICIU/AEI/10.13039/501100011033 [grants PID2019-106285 and PID2020-118127RB-I00]; MICIU/AEI/10.13039/501100011033 and EU Next Generation Funds/RTRP [grant PDC2021-121096]; and AGAUR, Catalonia [grant 2021SGR357]. Partial support was provided by NIH-NIEHS River Award R35 ES030443, NIH-NINDS U54 NS127758 (Counter Act Program), and NIH-NIEHS Superfund Program P42 ES004699 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health). We thank Xenia Sawkulycz (Manchester Metropolitan University, U.K.) for her contribution with the preparation of mCRP., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Activation of anti-inflammatory pathways by polyunsaturated fatty acid signaling may protect neurodevelopment in children prenatally exposed to methylmercury

  • Bartra, Clara
  • Llop, Sabrina
  • Kuligowski, Julia
  • Albiach-Delgado, Abel
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
  • Ballester, Ferran
  • Soler-Blasco, Raquel
  • Jora, Beatrice
  • Jarné-Ferrer, Júlia
  • Griñán-Ferré, Christian
  • Vázquez, Santiago
  • Pallàs, Mercè
  • Sanfeliu, Coral
Mercury is ubiquitous in the environment. Substantial levels of its organic form, methylmercury, pose a risk to fetal neurodevelopment through the maternal diet. Conversely, nutrients such as the polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (AA) promote neurodevelopment. We aimed to elucidate the neuroprotective role of PUFA signaling against prenatal methylmercury exposure in a Mediterranean fish-consuming area, addressing a critical gap in understanding nutritional modulation of neurotoxicity., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by the Spanish Ministerio de Ciencia: Innovación y Universidades and the Agencia Estatal de Investigación, MICIU/AEI/10.13039/501100011033 grants PID2019-106285RB, PID2020-118127RB and PID2022-139016OA-100, and grant PDC2021-121096 co-funded by the European Union - Next Generation EU/PRTR; the Spanish Instituto de Salud Carlos III (ISCIII) and co-funded by the Europen Union, grants FI21/00193 and CPII21/00003; the ISCIII grants FIS/FEDER 19/1338, 16/1288, 23/1578 and MS20/0006; the European Union grant H2020 874583; the Spanish Ministry of Universities (Margarita Salas Grant MS21-133) and co-funded by European Union - Next Generation EU; the Generalitat Valenciana, grants AICO/2020/285 and CIAICO/2021/132; and the Generalitat de Catalunya, AGAUR grant 2021-SGR-357., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain, A New Indication for Soluble Epoxide Hydrolase Inhibitors

  • Codony, Sandra|||0000-0003-0539-673X
  • Entrena, José M.|||0000-0002-4319-746X
  • Calvó-Tusell, Carla|||0000-0003-2681-8460
  • Jora, Beatrice
  • González-Cano, Rafael|||0000-0002-9657-4521
  • Osuna, Sílvia|||0000-0003-3657-6469
  • Corpas, Rubén|||0000-0002-7051-1493
  • Morisseau, Christophe
  • Pérez, Belén|||0000-0001-5801-1704
  • Barniol-Xicota, Marta|||0000-0001-7957-2199
  • Griñán-Ferré, Christian|||0000-0002-5424-9130
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel|||0000-0002-6500-792X
  • Martínez, Antón L.|||0000-0002-1595-3459
  • Loza, María Isabel|||0000-0003-4730-0863
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Verhelst, Steven H. L.|||0000-0002-7400-1319
  • Sanfeliu i Pujol, Coral|||0000-0002-9004-1206
  • Feixas, Ferran|||0000-0001-5147-0000
  • Hammock, Bruce D.|||0000-0003-1408-8317
  • Brea, José|||0000-0002-5523-1979
  • Cobos, Enrique J.
  • Vázquez, Santiago|||0000-0002-9296-6026
The soluble epoxide hydrolase (sEH) has been suggested as a pharmacological target for the treatment of several diseases, including pain-related disorders. Herein, we report further medicinal chemistry around new benzohomoadamantane-based sEH inhibitors (sEHI) in order to improve the drug metabolism and pharmacokinetics properties of a previous hit. After an extensive in vitro screening cascade, molecular modeling, and in vivo pharmacokinetics studies, two candidates were evaluated in vivo in a murine model of capsaicin-induced allodynia. The two compounds showed an anti-allodynic effect in a dose-dependent manner. Moreover, the most potent compound presented robust analgesic efficacy in the cyclophosphamide-induced murine model of cystitis, a well-established model of visceral pain. Overall, these results suggest painful bladder syndrome as a new possible indication for sEHI, opening a new range of applications for them in the visceral pain field.